Document Detail


Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome.
MedLine Citation:
PMID:  22287852     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
This case report describes how eculizumab reversed neurologic impairment and improved renal damage in severe atypical hemolytic uremic syndrome. A 50-year-old female, after presenting with diarrhea and abdominal pain, developed pancolitis, acute renal failure, and thrombocytopenia. The patient underwent total abdominal colectomy. Pathology confirmed ischemic colitis with scattered mesenteric microthrombi. Due to mental and respiratory decline, she remained intubated. Continuous venovenous hemodialysis was initiated. Renal failure, neurologic changes, hemolysis, thrombotic microangiopathy, and low complement levels all suggested atypical hemolytic uremic syndrome. Eculizumab 900 mg was administered intravenously on hospital day 6 and continued weekly for four doses followed by maintenance therapy. She recovered neurologically and renally after the third dose, and hematologically by the sixth dose. Her recovery has been sustained on long-term eculizumab treatment. In severe atypical hemolytic uremic syndrome, eculizumab safely reverses neurologic impairment and eliminates the need for dialysis. The optimal duration of treatment with eculizumab remains to be determined.
Authors:
Maro Ohanian; Christian Cable; Kathleen Halka
Publication Detail:
Type:  Journal Article     Date:  2011-05-24
Journal Detail:
Title:  Clinical pharmacology : advances and applications     Volume:  3     ISSN:  1179-1438     ISO Abbreviation:  Clin Pharmacol     Publication Date:  2011  
Date Detail:
Created Date:  2012-01-30     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101564865     Medline TA:  Clin Pharmacol     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  5-12     Citation Subset:  -    
Affiliation:
Department of Hematology and Oncology, Scott and White Healthcare, The Texas A&M Health Science Center College of Medicine, Temple, TX, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A case of cephalothin-associated urolithiasis.
Next Document:  Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or in...